1-Methylnicotinamide and nicotinamide: Two related anti-inflammatory agents that differentially affect the functions of activated macrophages

Archivum Immunologiae et Therapiae Experimentalis

Volumn 56, Issue 2, 2008, Pages 127-134

  Biedroń, Rafał ^a   Ciszek, Marta ^a   Tokarczyk, Marianna ^a   Bobek, Małgorzata ^a   Kurnyta, Maria ^a   Słominska, Ewa M ^b   Smoleński, Ryszard T ^b   Marcinkiewicz, Janusz ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

1 methylnicotinamide; Cytokines; Inflammation; Macrophages; Nicotinamide; ROS

Indexed keywords

1 METHYLNICOTINAMIDE; ANTIINFLAMMATORY AGENT; CYTOKINE; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; NICOTINAMIDE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE; REACTIVE OXYGEN METABOLITE; SCAVENGER; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CBA MOUSE; CELL VIABILITY; CHEMOLUMINESCENCE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG STRUCTURE; ENZYME LINKED IMMUNOSORBENT ASSAY; IN VITRO STUDY; INFLAMMATION; MACROPHAGE; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PROSTAGLANDIN RELEASE; STATISTICAL ANALYSIS; WESTERN BLOTTING;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CELLS, CULTURED; CYTOKINES; DINOPROSTONE; MACROPHAGE ACTIVATION; MACROPHAGES; MICE; MICE, INBRED CBA; NIACINAMIDE; NITRIC OXIDE; REACTIVE OXYGEN SPECIES;

EID: 42349098046     PISSN: 0004069X     EISSN: 16614917     Source Type: Journal    
DOI: 10.1007/s00005-008-0009-2     Document Type: Article

References (24)

1. Adamiec M., Adamus J., Ciebiada I., Denys A. and Gebicki J. (2006): Search for drugs of the combined anti-inflammatory and anti-bacterial properties: 1-methyl-N′-(hydroxymethyl) nicotinamide. Pharmacol. Rep., 58, 246-249.
2. Bryniarski K., Biedron R., Jakubowski A., Chłopicki S. and Marcinkiewicz J. (2008): Anti-inflammatory effect of 1-methylnicotinamide in contact hypersensitivity to oxazolone in mice; involvement of prostacyclin. Eur. J. Pharmacol., 578, 332-338.
3. 2 pathway. Br. J. Pharmacol., 152, 230-239.
4. Creeke P. I. and Seal A. J. (2005): Quantitation of the niacin metabolites 1-methylnicotinamide and l-methyl-2-pyridone-5-carboxamide in random spot urine samples, by ion-pairing reverse-phase HPLC with UV detection, and the implications for the use of spot urine samples in the assessment of niacin status. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 817, 247-253.
5. Daniel J., Marechal Y., Van Gool F., Andris F. and Leo O. (2007): Nicotinamide inhibits B lymphocyte activation by disrupting MAPK signal transduction. Biochem. Pharmacol., 73, 831-842.
6. Ding A. H., Nathan C. F. and Stuehr D. J. (1988): Release of reactive nitrogen intermediates from mouse peritoneal macrophages: comparison of activating cytokines and evidence for independent production. J. Immunol., 141, 2407-2412.
7. Eizirik D. L., Sandler S., Welsh N., Bendtzen K. and Hellerstrom C. (1994): Nicotinamide decreases nitric oxide production and partially protects human pancreatic islets against the suppressive effects of combinations of cytokines. Autoimmunity, 19, 193-198.
8. Fukuzawa M., Satoh J., Muto G., Muto Y., Nishimura S., Miyaguchi S., Qiang X. L. and Toyota T. (1997): Inhibitory effect of nicotinamide on in vitro and in vivo production of tumor necrosis factor-alpha. Immunol. Lett., 59, 7-11.
9. Gebicki J., Sysa-Jedrzejowska A., Adamus J., Wozniacka A., Rybak M. and Zielonka J. (2003): 1-Methylnicotinamide: a potent anti-inflammatory agent of vitamin origin. Pol. J. Pharmacol., 55, 109-112.
10. Hiromatsu Y., Sato M., Tanaka K., Ishisaka N., Kamachi J. and Nonaka K. (1993): Inhibitory effects of nicotinamide on intercellular adhesion molecule-1 expression on cultured human thyroid cells. Immunology, 80, 330-332.
11. Hiromatsu Y., Sato M., Yamada K. and Nonaka K. (1992): Inhibitory effects of nicotinamide on recombinant human interferon-gamma-induced intercellular adhesion molecule-1 (ICAM-1) and HLA-DR antigen expression on cultured human endothelial cells. Immunol. Lett., 31, 35-39.
12. Maiese K. and Chong Z. Z. (2003): Nicotinamide: necessary nutrient emerges as a novel cytoprotectant for the brain. Trends Pharmacol. Sci., 24, 228-232.
13. Otsuka A., Hanafusa T., Miyagawa J., Kono N. and Tarui S. (1991): Nicotinamide and 3-aminobenzamide reduce interferon-gamma-induced class II MHC (HLA-DR and -DP) molecule expression on cultured human endothelial cells and fibroblasts. Immunopharmacol. Immunotoxicol., 13, 263-280.
14. Papaccio G., Ammendola E. and Pisanti F. A. (1999): Nicotinamide decreases MHC class II but not MHC class I expression and increases intercellular adhesion molecule-1 structures in non-obese diabetic mouse pancreas. J. Endocrinol., 160, 389-400.
15. Pero R. W., Axelsson B., Siemann D., Chaplin D. and Dougherty G. (1999): Newly discovered anti-inflammatory properties of the benzamides and nicotinamides. Mol. Cell Biochem., 193, 119-125.
16. Sánchez-Fidalgo S., Villegas I., Martín A., Sánchez-Hidalgo M. and Alarcón de la Lastra C. (2007): PARP inhibition reduces acute colonic inflammation in rats. Eur. J. Pharmacol., 563, 216-223.
17. Schleupner C. J. and Glasgow L. A. (1978): Peritoneal macrophage activation indicated by enhanced chemiluminescence. Infect. Immun., 21, 886-895.
18. Slominska E. M., Adamski P., Lipinski M., Swierczynski J. and Smolenski R. T. (2006): Liquid chromatographic/mass spectrometric procedure for measurement of NAD catabolites in human and rat plasma and urine. Nucleosides Nucleotides Nucleic Acids, 25, 1245-1249.
19. Stanulovic M. and Chaykin S. (1971): Metabolic origins of the pyridones of N1-methylnicotinamide in man and rat. Arch. Biochem. Biophys., 145, 35-42.
20. Ungerstedt J. S., Blomback M. and Soderstrom T. (2003): Nicotinamide is a potent inhibitor of proinflammatory cytokines. Clin. Exp. Immunol., 131, 48-52.
21. Vague P., Picq R., Bernal M., Lassmann-Vague V. and Vialettes B. (1989): Effect of nicotinamide treatment on the residual insulin secretion in type 1 (insulin-dependent) diabetic patients. Diabetologia, 32, 316-321.
22. Wozniacka A., Szajerski P., Adamus J., Gebicki J. and Sysa-Jedrzejowska A. (2007): In search for new antipsoriatic agents: NAD topical composition. Skin Pharmacol. Physiol., 20, 37-42.
23. Wozniacka A., Wieczorkowska M., Gebicki J. and Sysa-Jedrzejowska A. (2005): Topical application of 1-methylnicotinamide in the treatment of rosacea: a pilot study. Clin. Exp. Dermatol., 30, 632-635.
24. Zackheim H. S. (1978): Topical 6-aminonicotinamide plus oral niacinamide therapy for psoriasis. Arch. Dermatol., 114, 1632-1638.